Luxe Med • Advanced Weight Management
The Next Generation of Weight-Loss Research
Retatrutide is an investigational once-weekly triple-receptor agonist being studied for obesity and metabolic health. Learn how it works and complete a private assessment to discuss legally available, clinically appropriate options with a licensed provider.
Why It Is Different
One Investigational Molecule. Three Metabolic Pathways.
Retatrutide is being studied for its combined activity at GLP-1, GIP, and glucagon receptors; pathways involved in hunger, fullness, glucose regulation, and energy use.
Appetite Support
GLP-1 and GIP activity may help decrease hunger and improve feelings of fullness.
Metabolic Support
The triple-receptor approach is being evaluated for effects on body weight and cardiometabolic markers.
Energy Expenditure
Glucagon-receptor activity is one feature researchers believe may influence energy use.
In Plain English
Why Everyone Is Talking About Retatrutide
Earlier incretin therapies generally target one or two receptor pathways. Retatrutide is designed to activate three. Researchers are studying whether that broader mechanism can produce greater weight reduction while supporting metabolic health.
Results vary, side effects can occur, and the medication remains investigational. A provider should review your medical history, current medications, prior GLP-1 use, goals, and contraindications before discussing any weight-management plan.
Hunger and fullness
Associated with appetite regulation, gastric emptying, and glucose-dependent insulin signaling.
Metabolic response
Involved in glucose-dependent insulin activity and nutrient signaling.
Energy use
Glucagon-receptor activity may influence energy expenditure and metabolism.
Simple Comparison
How the Pathways Compare
This table compares receptor targets—not guaranteed superiority, personal results, approval status, or safety.
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| GLP-1 receptor activity | Yes | Yes | Yes |
| GIP receptor activity | — | Yes | Yes |
| Glucagon receptor activity | — | — | Yes |
| FDA-approved products available | Yes | Yes | No—investigational |
| Provider evaluation required | Yes | Yes | Yes |
Personalized Review
Who Should Complete an Assessment?
An assessment helps your provider understand your goals and discuss approved or otherwise legally available options appropriate to your situation.
You have hit a plateau
You have made lifestyle changes or previously used a weight-management program with limited progress.
You have prior GLP-1 experience
You want a provider to review your response, side effects, dose history, and possible next steps.
You want medical oversight
You prefer a structured plan with eligibility screening, follow-up, and ongoing support.
You live in Nevada or Arizona
Luxe Med currently provides virtual services for eligible patients in NV and AZ.
Luxe Med Program
Clear, Simple Program Details
Final medication selection, lawful availability, dosing, and pricing are confirmed after provider review.
Displayed program price is subject to clinical eligibility, medication availability, applicable law, and final checkout confirmation.
How Luxe Med Works
From Assessment to Care Plan
Complete the assessment
Tell us about your goals, health history, and previous weight-loss treatments.
Provider review
A licensed provider evaluates eligibility, contraindications, and appropriate options.
Choose your plan
Review your personalized recommendation, program terms, and final price.
Begin with support
Receive instructions, follow-up care, and delivery when prescribed and legally available.
Questions
Retatrutide FAQ
What is retatrutide?
Retatrutide is an investigational once-weekly molecule designed to activate GLP-1, GIP, and glucagon receptors. It is being studied for obesity and other metabolic conditions.
Is retatrutide FDA-approved?
No. Retatrutide is investigational and is not currently FDA-approved. Availability to the public depends on successful trials and regulatory review.
How is it different from tirzepatide?
Tirzepatide activates GLP-1 and GIP receptors. Retatrutide is designed to activate GLP-1, GIP, and glucagon receptors. That third pathway is a key reason it is being studied.
How much weight did participants lose?
In Lilly’s May 2026 announcement for the TRIUMPH-1 Phase 3 trial, participants receiving 12 mg lost an average of 28.3% of body weight over 80 weeks. Trial findings do not predict an individual patient’s results.
What side effects may occur?
Clinical trials have commonly reported gastrointestinal effects with incretin-based therapies. Risks, contraindications, and side effects should be reviewed with a licensed provider.
Can I switch from another GLP-1?
Possibly, but a switch should never be automatic. Your provider should review your current medication, last dose, tolerance, response, and medical history.
Do I need labs?
Lab requirements depend on your history, symptoms, prior treatment, and provider assessment. Your provider will tell you what is required before or during treatment.
Your Next Step
Find the Right Weight-Management Option for You
Complete the Luxe Med assessment for a personalized provider review. No treatment or prescription is guaranteed.